Psychomotor retardation is a long established component of depression that can have
significant clinical and therapeutic implications for treatment. Due to its negative impact on …

The increasing number of individuals with comorbidities poses an urgent need to improve
the management of patients with multiple co-existing diseases. Among these comorbidities …

Dopamine is an important neuromodulator that exerts widespread effects on the central
nervous system (CNS) function. Disruption in dopaminergic neurotransmission can have …

Abstract Type-2 Diabetes (T2D) is characterized by insulin resistance and accompanied by
psychiatric comorbidities including major depressive disorders (MDD). Patients with T2D are …

Major depressive disorder (MDD) which is supposed to result from a complex interaction of
genetic and epigenetic, environmental and developmental factors is one of the most …

The antidepressant-like effect of trans-resveratrol, a phenolic compound present in
polygonum cuspidatum, was evaluated through behavioral and neurochemical methods …

Central dopaminergic and noradrenergic systems play essential roles in controlling several
forebrain functions. Consequently, perturbations of these neurotransmissions may contribute …

Multi-target drugs against selective multiple targets improve therapeutic efficacy, safety and
resistance profiles by collective regulations of a primary therapeutic target together with …

Both major depressive disorder and the anxiety disorders are major causes of disability and
markedly contribute to a significant global burden of the disease worldwide. In part because …

The current generation of antidepressant drugs acts predominantly by targeting the
serotonin transporter (SERT). The original trend to do this selectively (eg, with SSRIs or …